PRESS RELEASES

Date Title View
Toggle Summary Chimerix to Present at H.C. Wainwright 23rd Annual Global Investment Conference
DURHAM, N.C. , Sept. 07, 2021 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman , Chief Executive Officer of Chimerix and Mike Andriole , Chief
View HTML
Toggle Summary Chimerix Reports Second Quarter 2021 Financial Results and Provides Operational Update
– Received U.S. Food and Drug Administration (FDA) Approval for TEMBEXA ® (brincidofovir) for the Treatment of Smallpox – – Blinded Independent Central Review (BICR) of ONC201 Registration Cohort in Recurrent H3 K27M-mutant Glioma Expected in Fourth Quarter 2021 – – Conference Call at 8:30 a.m.
View HTML
Toggle Summary Chimerix to Present at 2021 Wedbush PacGrow Healthcare Conference
DURHAM, N.C. , Aug. 03, 2021 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman , Chief Executive Officer, will participate in a panel discussion
View HTML
Toggle Summary Chimerix to Report Second Quarter 2021 Financial Results and Provide an Operational Update on August 5, 2021
DURHAM, N.C. , July 29, 2021 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that it will host a live conference call and audio webcast on Thursday, August 5,
View HTML
Toggle Summary Chimerix Receives U.S. Food and Drug Administration Approval for TEMBEXA® (brincidofovir) for the Treatment of Smallpox
– First smallpox antiviral approved for all age groups, including infants, and patients who have difficulty swallowing – DURHAM, N.C. , June 04, 2021 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and
View HTML
Toggle Summary Chimerix to Present at Jefferies Virtual Healthcare Conference
DURHAM, N.C. , May 25, 2021 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman , Chief Executive Officer of Chimerix , will present a corporate
View HTML
Toggle Summary Chimerix Announces Upcoming Presentations at the American Society of Clinical Oncology 2021 Annual Meeting
DURHAM, N.C. , May 19, 2021 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced upcoming oral and poster presentations at the American Society of Clinical Oncology
View HTML
Toggle Summary Chimerix to Present at Cowen and Company 2nd Annual Virtual Oncology Innovation Summit
DURHAM, N.C. , May 13, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman , Chief Executive Officer, and Mike Andriole, Chief Business and
View HTML
Toggle Summary Chimerix Reports First Quarter 2021 Financial Results and Provides Operational Update
– BCV PDUFA Date Set for July 7 and ONC201 Blinded Independent Central Review Expected in Second Half of 2021 – – DSTAT COVID 19 Trial Advances to Cohort 3 at Higher Dose – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C. , May 06, 2021 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a
View HTML
Toggle Summary Chimerix to Report First Quarter 2021 Financial Results and Provide an Operational Update on May 6, 2021
DURHAM, N.C. , April 29, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that it will host a live conference call and audio webcast on Thursday, May 6, 2021
View HTML